Cytosorbents (CTSO) Free Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.81% |
| Dec 31, 2025 | -32.24% |
| Sep 30, 2025 | 5.89% |
| Jun 30, 2025 | -23.15% |
| Mar 31, 2025 | -0.13% |
| Dec 31, 2024 | 10.79% |
| Sep 30, 2024 | 13.29% |
| Jun 30, 2024 | -7.66% |
| Mar 31, 2024 | -1.48% |
| Dec 31, 2023 | -17.66% |
| Sep 30, 2023 | -14.97% |
| Jun 30, 2023 | -15.50% |
| Mar 31, 2023 | -4.90% |
| Dec 31, 2022 | -68.52% |
| Sep 30, 2022 | 6.80% |
| Jun 30, 2022 | -40.39% |
| Mar 31, 2022 | -37.91% |
| Dec 31, 2021 | -53.72% |
| Sep 30, 2021 | -2.92% |
| Jun 30, 2021 | -7.31% |
| Mar 31, 2021 | -16.41% |
| Dec 31, 2020 | 12.16% |
| Sep 30, 2020 | -8.22% |
| Jun 30, 2020 | 21.90% |
| Mar 31, 2020 | -10.78% |
| Dec 31, 2019 | -14.62% |
| Sep 30, 2019 | -22.14% |
| Jun 30, 2019 | -17.37% |
| Mar 31, 2019 | -40.70% |
| Dec 31, 2018 | -21.08% |
| Sep 30, 2018 | -36.38% |
| Jun 30, 2018 | -27.50% |
| Mar 31, 2018 | -24.69% |
| Dec 31, 2017 | -0.97% |
| Sep 30, 2017 | -31.90% |
| Jun 30, 2017 | -12.24% |
| Mar 31, 2017 | -13.90% |
| Dec 31, 2016 | 0.83% |
| Sep 30, 2016 | -17.74% |
| Jun 30, 2016 | -13.96% |
| Mar 31, 2016 | -17.14% |
| Dec 31, 2015 | -28.41% |
| Sep 30, 2015 | -30.12% |